Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 5OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Breast Neoplasms 66Neoplasms 49Stomach Neoplasms 45Colorectal Neoplasms 42Carcinoma, Non-Small-Cell Lung 37Lung Neoplasms 30Uterine Cervical Neoplasms 28Rectal Neoplasms 28Carcinoma, Hepatocellular 25Prostatic Neoplasms 24Recurrence 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Ovarian Neoplasms 18Neoplasm Metastasis 16Colonic Neoplasms 16Esophageal Neoplasms 15Urinary Bladder Neoplasms 14Thyroid Neoplasms 14Pancreatic Neoplasms 14Nasopharyngeal Carcinoma 14Leukemia, Myeloid, Acute 13Head and Neck Neoplasms 13Small Cell Lung Carcinoma 11Papillomavirus Infections 11Multiple Myeloma 11Motor Activity 11Melanoma 11Lymphoma 11Sarcoma 10Lymphoma, Non-Hodgkin 10

Interventions

Irinotecan 1Etoposide 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × OTHER_GOV × Gastro-enteropancreatic neuroendocrine tumor × Clear all
NCT03963193 2019-05-24

Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type

Henan Cancer Hospital

Phase 2 Unknown
112 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡